Obesity Clinical Trials

Find Obesity Clinical Trials Near You

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

Status: Recruiting
Location: See location...
Intervention Type: Other, Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 65
Healthy Volunteers: t
View:

• Willingness to provide informed consent to participate in the BATNAD study

• Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent

• Age 30-55 (sedentary lifestyle)

• BMI = 18-25 kg/m2 (normal-weight subjects)

• BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity)

Locations
Other Locations
Finland
Turku PET Centre
RECRUITING
Turku
Contact Information
Primary
Mueez U-Din, PhD
mueez.udin@utu.fi
+358-417027723
Backup
Kirsi Virtanen, MD, PhD
kianvi@utu.fi
+358407626564
Time Frame
Start Date: 2024-11-20
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 68
Treatments
Placebo_comparator: Placebo
Experimental: Oral NAD+ precursor supplementation
Related Therapeutic Areas
Sponsors
Leads: University of Turku

This content was sourced from clinicaltrials.gov